Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets 02:14:35 06/10/21 am AEDT			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

19/08	Cosmos Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Cosmos Health Advances its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C And B2B Channels	CI

Market Cap	10.99M 9.41M 8.78M 8.06M 15.14M 1.05B 15.44M 104M 40.62M 527M 41.28M 40.38M 1.75B	P/E 2026 *	-0.92x	P/E 2027 *	2.76x
Enterprise Value	10.99M 9.41M 8.78M 8.06M 15.14M 1.05B 15.44M 104M 40.62M 527M 41.28M 40.38M 1.75B	EV / Sales 2026 *	0.14x	EV / Sales 2027 *	0.1x
Free-Float	78.25%	Yield 2026 *	-	Yield 2027 *	-

19/08	Cosmos Health Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/07	Cosmos Health Advances its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C And B2B Channels	CI
14/07	Cosmos Health Inc. And Libytec Pharmaceutical S.A. Enters Distribution And Promotion Agreement For DIABIT-IS X In Greece	CI
14/07	Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug	MT
11/07	Cosmos Health Inc. Launches Subscription-Based Purchasing Model for Its Proprietary Consumer Health Brands	CI
11/07	Cosmos Health Launches Subscription-Based Purchasing Model	MT
08/07	Cosmos Health Inc. Provides Preliminary Revenue Guidance for the Second Quarter and First Half 2026	CI
03/07	Cosmos Health Expands Share Buyback to 3.4 Million Shares	MT
01/07	Cosmos Health Inc. announces an Equity Buyback for $5 million worth of its shares.	CI
30/06	Cosmos Health Inc. authorizes a Buyback Plan.	CI
27/06	Cosmos Health Signs Qatar Distribution Deal With IMC	MT
27/06	Cosmos Health Inc. Signs Distribution Agreement with International Medical Company, and Secures Initial Purchase Order of 31,000 Sky Premium Life Units	CI
24/06	Cosmos Health to Deploy AI-Powered Call Center at Pharma Distribution Unit	MT

11:30pm	Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term	GL
19/08	Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway	GL
19/08	Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway	AQ
28/07	Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels	GL
21/07	Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units	GL

Cosmos Holdings Inc. Stock OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Quarterly revenue - Rate of surprise

30/11/24	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
28/11/24	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
05/12/22	Pelè non è in cure palliative - figlia
01/12/22	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	26/02/2016
Georgios Terzis DFI	Director of Finance/CFO	43	11/11/2020
Nikolaos Bardakis COO	Chief Operating Officer	56	01/02/2023

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	58	13/01/2014
Grigorios Siokas CHM	Chairman	60	26/02/2016
John Hoidas BRD	Director/Board Member	59	18/11/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	10.99M
MCKESSON CORPORATION	-0.62%	-0.76%	+20.94%	+99.64%	99.53B
CARDINAL HEALTH, INC.	-1.66%	-0.10%	+51.03%	+165.70%	54.62B
SIGMA HEALTHCARE LIMITED	0.00%	-2.03%	+2.47%	+279.08%	23.75B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+1.77%	+0.60%	-11.90%	-13.45%	8.13B
HUADONG MEDICINE CO., LTD	+4.98%	+1.42%	-34.86%	-20.49%	7.42B
SINOPHARM GROUP CO. LTD.	-0.96%	-1.01%	-15.75%	-21.79%	6.66B
H. LUNDBECK A/S	-4.19%	-3.14%	+4.58%	+18.88%	6.55B
GALENICA AG	+2.35%	+2.29%	-2.88%	+18.65%	5.03B
MEDIPAL HOLDINGS CORPORATION	+0.56%	+3.38%	+8.29%	+18.74%	3.71B
Average	-0.24%	+0.17%	+2.44%	+60.55%	23.93B
Weighted average by Cap.	-0.52%	-1.31%	+20.97%	+118.27%

	2026 *	2027 *
Net sales	80.8M 69.18M 64.55M 59.23M 111M 7.73B 113M 766M 298M 3.87B 303M 297M 12.83B	111M 94.87M 88.51M 81.22M 153M 10.6B 156M 1.05B 409M 5.31B 416M 407M 17.59B
Net income	-	-
Net Debt	-	-